First and Last Author

1. Ilhan A, Gartner W, Nabokikh A, Daneva T, Majdic O, Cohen G, Bohmig GA, Base W, Horl WH, Wagner L (2008).
Localization and characterization of the novel protein encoded by C20orf3
Biochem J, 414:485-495

2. Ilhan A, Gartner W, Neziri D, Czech T, Base W, Horl WH, Wagner L (2009).
Angiogenic factors in plasma of brain tumour patients
Anticancer Res, 29:731-736

3. Ilhan A, Nabokikh A, Maj M, Vidakovic M, Nielsen JH, Prikoszovich T, Niederle B, Base W, Luger A, Wagner L (2009).
CXCL12/SDF-1 over-expression in human insulinomas and its biological relevance
Mol Cell Endocrinol, 298:1-10

4. Ilhan A, Rasul S, Dimitrov A, Handisurya A, Gartner W, Baumgartner-Parzer S, Wagner L, Kautzky-Willer A, Base W (2010).
Plasma Neuropeptide Y levels differ in distinct diabetic conditions
Neuropeptides, 44(6):485-9

5. Ilhan A, Neziri D, Maj M, Mazal PR, Susani M, Base W, Gartner W, Wagner L (2010).
Expression of secretagogin in clear-cell renal cell carcinomas associates with a high metastasis rate
Human Pathology, 42(5):641-8

6. Ilhan A, Furtner J, Birner P, Rössler K, Marosi C, Preusser M (2011).
Myxopapillary ependymoma with pleuropulmonary metastases and high plasma glial fibrillary acidic protein levels
Journal of Clinical Oncology, 20;29(30):e756-7 (Case Report)

7. Ilhan-Mutlu A, Wagner L, Widhalm G, Wöhrer A, Bartsch S, Czech T, Heinzl H, Leutmezer F, Prayer D, Marosi C, Base W, Preusser M (2012).
Exploratory investigation of eight circulating plasma markers in brain tumor patients
Neurosurgical Review, 36(1):45-56

8. Ilhan-Mutlu A, Wagner L, Wöhrer A, Furtner J, Widhalm G, Marosi C, Preusser M (2012).
Plasma MicroRNA-21 concentration may be a useful biomarker in glioblastoma patients
Cancer Investigation, 30 (8); 615-621

9. Ilhan-Mutlu A, Wagner L, Wöhrer A, Jungwirth S, Marosi C, Fischer P, Preusser M (2012).
Blood alterations preceding clinical manifestation of glioblastoma
Cancer Investigation, 30 (9): 625-639

10. Ilhan-Mutlu A, Wöhrer A, Berghoff AS, Widhalm G, Marosi C, Wagner L, Preusser M (2013).
Comparison of microRNA expression levels between initial and recurrent glioblastoma specimens
Journal of Neurooncology, 112 (3): 347-354

11. Ilhan-Mutlu A, Berghoff AS, Furtner J, Dieckmann K, Slavc I, Czech T, Marosi C, Wagner L, Preusser M (2013).
High plasma-GFAP levels in metastastic myxopapillary ependymoma
Journal of Neurooncology, 113 (3):359-363

12. Ilhan-Mutlu A, Preusser M, Schoppmann SF, Asari R, Ba-Ssalamah A, Schwameis K, Pluschnig U, Birner P, Püspök A, Zackerl J, Hejna M (2013).
Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capacitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract
Anticancer Research, 33 (8): 3455-3459

13. Ilhan-Mutlu A, Starlinger P, Perkmann T, Schoppmann SF, Preusser M, Birner P (2014).
High plasma fibrinogen levels and blood platelet counts are associated with better histological response to neoadjuvant therapy in esophageal cancer
Biomarkars in Medicine, 9:327-35

14. Ilhan-Mutlu A, Tezcan G, Schoppmann SF, Preusser M, Spyridoula K, Karanikas G, Birner P (2015).
MicroRNA-21 expression is elevated in esophageal adenocarcinoma after neoadjuvant chemotherapy
Cancer Investigation, 33:246-50

15. Ilhan-Mutlu A, Siehs C, Berghoff A, Ricken G, Widhalm G, Wagner L, Preusser M (2015).
Expression profiling of angiogenesis-related genes in brain metastasis of lung cancer and melanoma
Tumor biology, 37(1):1173-82

16. Ilhan-Mutlu A, Osswald M, Liao Y, Gömmel M, Reck M, Miles D, Mariani P, Gianni L, Lutiger B, Nendel V, Srock S, Perez-Moreno P, Thorsen F, von Baumgarten L, Preusser M, Wick W, Winkler F (2016).
Bevacizumab prevents brain metastases formation in lung adenocarcinoma
Mol Cancer Ther. 15(4):702-10

17. Ilhan-Mutlu A, Taghizadeh H, Beer A, Dolak W, Ba-Ssalamah, Schoppmann SF, Hejna M, Birner P, Preusser M (2017).
Correlation of trastuzumab-based treatment with clinical charachteristics and and prognosis in HER2-positive gastric and gastroesophageal junction cancer: A retrospective single center analysis
Cancer Biol Ther,   19(3):169-74

18. Taghizadeh H, Lampichler K, Beer A, Preusser M, Ilhan-Mutlu A (2019)
A case report of pseudo-progression after pembrolizumab in metastatic gastric cancer and a review of immunotherapy in gastroesophageal tumors
MEMO, in press

19. Puhr HC, Wolf P, Berghoff AS, Schoppmann SF, Preusser M, Ilhan-Mutlu A (2020)
Elevated free thyroxin levels are associated with poorer overall survival in patients with gastroesophageal cancer: A retrospective single center analysis
Hormones and Cancer, in press

20. Puhr HC, Pablik E, Berghoff A, Schoppmann SF, Jomrich G, Preusser M, Ilhan-Mutlu A (2020)
Viennese risk prediction score for Advanced Gastroesophageal carcinoma based on Alarm Symptoms (VAGAS score) - Characterization of alarm symptoms in advanced gastroesophageal cancer and its correlation with outcome
ESMO open, in press

21. Baumgartner R, Taghizadeh H, Jomrich G, Schoppmann SF, Preusser M, Ilhan-Mutlu A (2020)
Utilization and efficacy of palliative chemotherapy for locally advanced or metastatic gastroesophageal carcinoma
Anticancer Research, in press


1. Artwohl M, Lindenmair A, Roden M, Waldhausl WK, Freudenthaler A, Klosner G, Ilhan A, Luger A, Baumgartner-Parzer SM (2009).
Fatty acids induce apoptosis in human smooth muscle cells depending on chain length, saturation, and duration of exposure
Atherosclerosis, 202:351-362

2. Gartner W, Vila G, Daneva T, Nabokikh A, Koc-Saral F, Ilhan A, Majdic O, Luger A, Wagner L (2007).
New functional aspects of the neuroendocrine marker secretagogin based on the characterization of its rat homolog
Am J Physiol Endocrinol Metab, 293:E347-354

3. Nabokikh A, Ilhan A, Bilban M, Gartner W, Vila G, Niederle B, Nielsen JH, Wagner O, Base W, Luger A, Wagner L (2007).
Reduced TGF-beta1 expression and its target genes in human insulinomas
Exp Clin Endocrinol Diabetes, 115:674-682

4. Maj M, Gartner W, Ilhan A, Neziri D, Attems J, Wagner L (2010).
Expression of Tau in insulin secreting cells and its interaction with the calcium binding protein secretagogin
J Endocrinol, 205(1):25-36

5. Neziri D, Ilhan A, Maj M, Majdic O, Baumgartner-Parzer S, Cohen G, Base W, Wagner L (2010).
Cloning and molecular characterization of Dashurin encoded by C20orf116, a PCI-domain containing protein
Biochim Biophys Acta, 1800(4):430-438

6. Gartner W, Ilhan A, Neziri D, Base W, Weissel M, Wohrer A, Heinzl H, Waldhor T, Wagner L, Preusser M (2010).
Elevated blood markers 1 year before manifestation of malignant glioma
Neuro Oncol, 44(6):485-9

7. Rasul S, Ilhan A, Reiter MH, Baumgartner-Parzer S, Kautzky-Willer A (2011).
Relations of adiponectin to the levels of metabolic parameters and sexual hormones in elderly type 2 diabetic subjects
Gender Medicine, 8(2):93-102

8. Rasul S, Reiter MH, Ilhan A, Lampichler K, Wagner L, Kautzky-Willer A (2011).
Circulating angiopoietin-2 and soluble Tie-2 in type 2 diabetes mellitus: a cross-sectional study
Cardiovasc Diabetol, 23;10:55

9. Lampichler K, Ilhan A, Lang R, Daneva T, Wagner L, Knosp E, Niederle B, Baumgartner-Parzer SM (2011).
Evaluation of MEN1 risk in individuals bearing R171Q. R171Q - single nucleotide polymorphism (SNP) or not SNP - that is the question
Clin Endocrinol (Oxf), 75(2):274
10. Capper D, Berghoff AS, Magerle M, Ilhan A, Wöhrer A, Hackl M, Pichler J, Pusch S, 5eyer J, Habel A, Petzelbauer P, Birner P, von Deimling A, Preusser M (2011).
Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases
Acta Neuropathol, 123(2):223-233
11. Maj M, Milenkovic I, Bauer J, Berggard T, Veit M, Ilhan-Mutlu A, Wagner L, Tretter V (2012).
Novel insights into the distribution and functional aspects of the calcium binding protein secretagogin from studies on rat brain and primary neuronal cell culture
Frontiers in Molecular Neurosciences, 5 (84)
12. Berghoff AS, Bago-Horvath Z, Ilhan-Mutlu A, Magerle M, Dieckmann K, Marosi C, Birner P, Widhalm G, Steger GG, Zielinski CC, Bartsch R, Preusser M (2012).
Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors
British Journal of Cancer, 107 (9): 1454-1458
13. Spanberger T, Berghoff AS, Dinhof C, Ilhan-Mutlu A, Magerle M, Hutterer M, Pichler J, Wöhrer A, Hackl M, Widhalm G, Hainfellner JA, Dieckmann K, Marosi C, Birner P, Prayer D, Preusser M (2012).
Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases
Clinical and Experimental Metastasis,  30 (4):357-368 2013
14. Rasul S, Ilhan A, Wagner L, Luger A, Kautzky-Willer A (2012).
Diabetic polyneuropathy relates to bone metabolism and markers of bone turnover in elderly patients with type 2 diabetes: greater effects in male patients
Gender Medicine, 9(82): 187-196
15. Rasul S, Ilhan A, Reiter MH, Todoric J, Farhan S, Esterbauer H, Kautzky-Willer A (2012).
Levels of fetuin-A relate to the levels of bone turnover biomarkers in male and female patients with type 2 diabetes
Clinical Endocrinology, 76 (4): 499-505
16. Berghoff AS, Spanberger T, Ilhan-Mutlu A, Magerle M, Hutterer M, Wöhrer A, Hackl M, Widhalm G, Dieckmann K, Marosi C, Birner P, Prayer D, Preusser M (2013).
Preoperative diffusion-weighted imaging of single brain metastases correlates with patient survival times
PLoS ONE, 8 (2):e55464
17. Berghoff A, Magerle M, Ilhan-Mutlu A, Dinhof C, Widhalm G, Dieckman K, Marosi C, Woehrer A, Hackl M, Zoechbauer-Mueller S, Preusser M, Birner P (2013).
Frequent overexpression of ERBB-Receptor family members in brain metastases of non-small cell lung cancer patients
APMIS, 121 (12). 1144-1152

18. Preusser M, Berghoff AS, Ilhan-Mutlu A, Dinhof C, Magerle M, Marosi, C, Hejna M, Capper D, von Deimling A, Schoppmann SF, Birner P (2013).
Brain metastases of gastro-oesophageal cancer: evaluation of molecules with relevance for targeted therapies.
Anticancer Res, 33 (3):1065-1071
19. Preusser M, Berghoff AS, Ilhan-Mutlu A, Magerle M, Dinhof C, Widhalm G, Dieckmann K, Marosi C, Woehrer A, Hackl M, Zöchbauer-Müller S, von Deimling A, Schoppmann SF, Zielinski CC, Streubel B, Birner P (2013).
ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer
Lung Cancer, 80 (3): 278-283

20. Preusser M, Berghoff AS, Berger W, Ilhan-Mutlu A, Dinhof C, Widhalm G, Dieckmann K, Wöhrer A, Hackl M, von Deimling A, Streubel B, Birner P (2014).
High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer
Lung Cancer,  83 (1):83-89

21. Berghoff AS, Ilhan-Mutlu A, Wöhrer A, Hackl M, Widhalm G, Hainfellner JA, Dieckmann K, Melchardt T, Dome B, Heinzl H, Birner P, Preusser M (2014).
Prognostic significance of Ki67 proliferation index, HIF1 alpha index and microvascular density in patients with non-small cell lung cancer brain metastases
Strahlentherapie und Onkologie, 190 (7):676-85

22. Schoppmann SF, Ricken G, Ilhan-Mutlu A, Nirtl N, Streubel B, Preusser M, Birner P (2014)
Downregulation of CIC does not associate with overexpression of ETV1 or MAP kinase pathway activation in gastrointestinal stromal tumors
Cancer Investigation, 32 (7): 363-368

23. Berghoff AS, Ilhan-Mutlu A, Dinhof C, Magerle M, Hackl M, Widhalm G, Hainfellner JA, Dieckmann K, Pichler J, Hutterer M, Melchardt T, Bartsch R, Zielinski CC, Birner P, Preusser M (2014)
Differential role of angiogenesis and tumor cell proliferation in brain metastases according to primary tumor type: analysis of 639 cases
Neuropathology and Applied Neurobiology, 41(1):e41-55

24. Pajenda S, Ilhan-Mutlu A, Preusser M, Roka S, Druml W, Wagner L (2015).
NephroCheck data compared to serum creatinine in various clinical settings
BMC Nephrol. 9;16:206

25. Neziri D, Pajenda S, Amuge R, Ilhan A, Wewalka M, Hörmann G, Zauner C, Wagner L (2016).
DDRGK1 in urine indicative of tubular cell injury in intensive care patients with serious infections
J Nephropathol 5(2):65-71.

26. Jomrich G, Hollenstein M, John M, Baierl A, Paireder M, Kristo I, Ilhan-Mutlu A, Asari R, Preusser M, Schoppmann SF (2018)
The modified glasgow prognostic score is an independent prognostic indicator in neoadjuvantly treated adenocarcinoma of the esophagogastric junction.
Oncotarget 8;9(6):6968-6976

27. Jomrich G, Maroske F, Stieger J, Preusser M, Ilhan-Mutlu A, Winkler D, Kristo I, Paireder M, Schoppmann SF (2018)
MK2 and ETV1 Are Prognostic Factors in Esophageal Adenocarcinomas.
J Cancer  1;9(3):460-468

28. Handisurya A, Rumpold T, Caucig-Lütgendorf C, Flechl B, Preusser M, Ilhan-Mutlu A, Dieckmann K, Widhalm G, Grisold A, Wöhrer A, Hainfellner J, Ristl R, Kurz C, Marosi C, Gessl A, Hassler M (2019)
Are hypothyroidism and hypogonadism clinically relevant in patients with malignant gliomas? A longitudinal trial in patients with glioma
Radiother Oncol 130:139-148 in press
29. Tamandl D, Fueger B, Haug A, Schmid R, Stift J, Schoppmann SF, Ilhan-Mutlu A, Ba-Ssalamah A (2019)
A Diagnostic Algorithm That Combines Quantitative 18F-FDG PET Parameters and Contrast-Enhanced CT Improves Posttherapeutic Locoregional Restaging and Prognostication of Survival in Patients With Esophageal Cancer
Clin Nucl Med 44(1):e13-e21 in press

30. Jomrich G, Paiereder M, Kristo I, Baierl A, Ilhan-Mutlu A, Preusser M, Asari R, Schoppmann SF (2019)
High systemic immune-inflammation index is an advanced prognostic factor for patients with gastroesophageal adenocacarcinoma
Annals of Surgery Aug 16

31. Paiereder M, Jomrich G, Kristo I, Asari R, Rieder E, Beer A, Ilhan-Mutlu A, Preusser M, Schmidt R, Schoppmann SF (2020)
Modification of preoperative Radiochemotherapy for esophageal cancer (CROSS Schema) is safe and efficient with no impact on surgical morbidity
Strahlentherapie und Onkologie, 2020 February


1. Ilhan A, Wagner L, Gartner W (2009).
CRYAB, (Crystallin, Alpha B)
Atlas of Genetics and Cytogenetics in Oncology and Haematology

2. Gartner W, Ilhan A, Maj M, Attems J, Wagner L (2010).
Secretagogin: Multiple aspects of a novel neuroendocrine marker
Current Trends in Endocrinology
3. Maj M, Ilhan A, Neziri D, Gartner W, Berggard T, Attems J, Base W, Wagner L (2010).
Age related changes in pancreatic beta cells: A putative extra-cerebral site of Alzheimer's pathology
World J Diabetes. 2011 Apr 15;2(4):49-53.

4. Preusser M, Capper D, Ilhan-Mutlu A, Berghoff AS, Birner P, Bartsch R, Zielinski C, Mehta MP, Winkler F, Wick W, von Deimling A (2012).
Brain metastases: pathobiology and emerging targeted therapies.
Acta Neuropathol, 123(2): 205-222
5. Ilhan-Mutlu A, Wagner L, Preusser M (2013).
Circulating biomarkers of CNS Tumours: an Update
Biomarkers in Medicine, 7 (2):267-285

6. Puhr HC, Ilhan-Mutlu A (2019).
New emerging targets in cancer immunotherapy: Role of anti-LAG
ESMO open, in press

7. Puhr HC, Ilhan-Mutlu A (2019).
Molecular profiling in gastroesophageal cancer: Clinical routine and future perspective
MEMO, in press

8. Puhr HC, Preusser M, Prager G, Ilhan-Mutlu A (2020)
New treatment options for advanced gastroesophageal tumors: Mature for the current practice?
Cancers, in press

Publications in non-peer-reviewed journals

1.     Ilhan-Mutlu, A: ESMO 2019 Gastroesophageal Tumors Highlights, Spectrum Onkologie, 12/19

2.     Ilhan-Mutlu, A; Neue Therapieoptionen bei Magenkarzinom, Schon Reif für die Praxis? JATROS Onkologie, 10/19

3.     Ilhan-Mutlu, A; Neue Therapieoptionen bei Magenkarzinom, Sind sie schon reif für die Praxis? Spectrum Onkologie, 10/19

4.     Ilhan-Mutlu, A; Neue Therapieoptionen bei Magenkarzinom, MEMO Springer, 04/2019

5.     Ilhan-Mutlu, A; Update Immuntherapie bei Magenkarzinom, Spectrum Onkologie, 10/2018

6.     Ilhan-Mutlu, A; Steckbrief: LAG-3, Spectrum Onkologie, 09/2018

7.     Ilhan-Mutlu, A; Round Table für die junge Onkologie, Spektrum Onkologie, 08/2017

8.     Ilhan-Mutlu, A; Drei neue Upper-GI Studien, Krebs:hilfe!, 07/2017

9.     Ilhan-Mutlu, A; In kürzerer Zeit kommt oft mehr raus, Krebs:hilfe!, 04/2017

10.  Ilhan-Mutlu, A; Druggable Targets bei hochmalignen Gliomen, Spektrum Onkologie, 05/2017

11.  Ilhan-Mutlu, A; Immuntherapie des Magenkarzinoms, Spektrum Onkologie, 02/2017

12.  Ilhan-Mutlu, A; Immuntherapie des Magenkarzinoms, Universum InnereMedizin, 02/2017

13.  Ilhan-Mutlu, A; Immunonkologie, DFP Special, Editor, Spektrum Onkologie, 2017

14.  Ilhan-Mutlu, A; Prevention of brain metastasis by inhibiton of angiogenesis?, WFNO Magazine 06/2016

15.  Ilhan-Mutlu, A; Highlights zu gastroösophagealen Tumoren, JATROS Haematologie & Onkologie, 04/2013

16.  Ilhan-Mutlu, A; Österreischische Topbeitraege ASCO 2013, Krebs:hilfe!, 04/2013

17.  Ilhan-Mutlu, A; Biomarker maligner Gliome, Krebs:hilfe!, 01/2013

18.  Ilhan-Mutlu, A; The role for blood tests in brain tumours?, International Brain Tumour Alliance, World Edition 2013